Does immune serum globulin confer protection against skin diseases?
- 1 August 2000
- journal article
- research article
- Published by Wiley in International Journal of Dermatology
- Vol. 39 (8) , 628-631
- https://doi.org/10.1046/j.1365-4362.2000.00983.x
Abstract
Background Following a case of serologically proven hepatitis A in a food‐handling worker serving several military bases in the same vicinity, the entire military population was vaccinated with immune serum globulin (ISG).Objective To evaluate the effectiveness of ISG in preventing skin disease.Methods The data for this study were drawn from the military archives of the Medical Corps. The population of the bases was followed for a period of 3 months after immunization. Rates of selected skin diseases were compared with those of a nearby base during the same period, and with those in the population of the same bases a year earlier.Results The rates of several skin diseases (bacterial skin infections, dermatitis and eczema, fungal infections, acne, warts, nail disorders, and nonspecific skin diseases) among the vaccinated population were significantly lower when compared to the historical control group and to the contemporary control group of the nearby base.Conclusions ISG provides a protecting effect for skin diseases, especially those of infectious origin.Keywords
This publication has 22 references indexed in Scilit:
- Epidemiology of Hepatitis A in IsraelPublished by S. Karger AG ,2015
- Can Prophylactic Application of Immunoglobulin Decrease Radiotherapy-Induced Oral Mucositis?American Journal of Clinical Oncology, 1997
- Respiratory syncytial virus–enriched globulin for the prevention of acute otitis media in high-risk childrenThe Journal of Pediatrics, 1996
- Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulinJournal of the Neurological Sciences, 1996
- Use of Immunoglobulins in Prevention and Treatment of Infection in Critically III Patients: Review and CritiqueClinical Infectious Diseases, 1991
- Biologic Response Modifiers in Primary Immunodeficiency DisordersAnnals of Internal Medicine, 1991
- Rise in the Incidence of Viral Hepatitis in Israel Despite Improved Socioeconomic ConditionsClinical Infectious Diseases, 1989
- PREVENTION OF POST-TRANSFUSION NON-A, NON-B HEPATITIS BY NON-SPECIFIC IMMUNOGLOBULIN IN HEART SURGERY PATIENTSThe Lancet, 1988
- IV Immune Globulin: Efficacy and SafetyHospital Practice, 1987
- USE OF NORMAL IMUNOGLOBULIN IN AN ECHOVIRUS 11 OUTBREAK IN A SPECIAL-CARE BABY UNITThe Lancet, 1983